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Alopecia areata is a multifactorial autoimmune disease
causing non-scarring hair loss. Recent genome-wide
association studies have pointed to connections
between alopecia areata and other autoimmune dis-
orders. Research of clinical conditions positively and
negatively associated with alopecia areata is crucial for
discovering the pathological mechanisms of disease
and further treatment options.
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OBJECTIVE
To evaluate the prevalence of comorbid systemic conditions
and sun-induced skin cancers in alopecia areata (AA) patients
from a tertiary-care hospital data (Gilhar et al., 2007;
Martinez-Mir et al., 2007; Petukhova et al., 2010; Jabbari
et al., 2013).
RESULTS
In our study population of 584 AA patients, 400 (68.50%)
were female. The average age at presentation was
35.54±19.28 years. AA was the most common manifestation
(94.7%), followed by alopecia universalis (3.25%), and alo-
pecia totalis (2.05%). The data were compared with a control
group, where 126 (73.25%) were women; the control group’s
average age was 35.80±15.56. Common comorbid condi-
tions in patients with AA are presented in Table 1. The most
common are atopic conditions (allergic rhinitis 17.12
vs. 11.62% in control group (P¼0.08); eczema 14.20 vs.
4.07% (Po0.01)), autoimmune (thyroid disorders 18.80 vs.
7.56% (Po0.01)); psychological (anxiety 13.70 vs. 9.88%
(P¼ 0.18); depression 14.72 vs. 11.44% (P¼ 0.19)), nutritional
deficiencies (vitamin D deficiency 39 vs. 12.79% (Po0.01);
anemia (16.80 vs. 7.56% (Po0.01)), and gastrointestinal
disorders (celiac disease 0.86 vs. 0.58% (P¼ 0.37)). Patients
with AA had non-melanoma skin cancers (basal-cell carci-
noma 1.54 vs. 3.48% (P¼ 0.10), squamous-cell carcinoma
0.51 vs. 0.58% (P¼ 0.012)) and malignant melanoma (0.51
vs. 1.74% (P¼ 0.10)) (Table 2). Significant increases in
AA versus control were seen in eczema (Po0.01), thyroid
conditions (Po0.01), vitamin D deficiency (Po0.01), and
anemia (Po0.0027). There seems to be a lower rate of skin
cancers in patients with AA, in particular squamous-cell
carcinomas (Po0.012).
DISCUSSION
In this study we identified a high prevalence of comorbid
conditions among individuals with AA treated at a single
tertiary center. Eczema, asthma, thyroid conditions, vitamin D
deficiency, and anemia were more common in patients with
REVIEW
Table 1. Summary of systemic comorbid conditions in
patients with alopecia areata
Characteristic
AA n=584
(%)
Control
n=172 (%) P-value OR (95% CI)
Atopy
Allergic rhinitis 100 (17.12) 20 (11.62) P=0.0830 1.57 (0.94–2.62)
Eczema 83 (14.20) 7 (4.07) P=0.0003 3.91 (1.77–8.62)
Asthma 79 (13.50) 14 (8.14) P=0.0586 1.77 (0.97–3.20)
Autoimmune disorders
Thyroid 110 (18.80) 13 (7.56) P=0.0004 2.84 (1.55–5.18)
Diabetes mellitus 21 (3.60) 14 (8.14) P=0.0127 0.42 (0.21–0.85)
Psoriasis 15 (2.56) 2 (1.16) P=0.1457 2.24 (0.51–9.89)
Psychological problem
Anxiety 80 (13.70) 17 (9.88) P=0.1882 1.45 (0.83–2.52)
Depression 86 (14.72) 19 (11.04) P=0.1928 1.41 (0.84–2.41)
Sleep problems 64 (11.00) 16 (9.30) P=0.0936 1.61 (0.92–2.83)
Deficiency
Vitamin D 228 (39.00) 22 (12.79) P<0.001 13.72 (6.32–29.82)
Anemia 98 (16.80) 13 (7.56) P=0.0027 2.45 (1.34–4.49)
Iron 43 (7.36) 5 (2.91) P=0.0351 2.65 (1.04–6.81)
Gastrointestinal disease
Celiac 5 (0.86) 1 (0.58) P=0.377 1.48 (0.17–12.73)
Abbreviations: AA, alopecia areata; CI, confidence interval; OR, odds ratio.
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AA. There seems to be a lower rate of skin cancers in patients
with AA, in particular squamous-cell carcinomas. Awareness
of conditions commonly associated with AA is necessary for
dermatologists when they evaluate patients. Larger studies are
needed to confirm the significance of these findings.
MATERIALS AND METHODS
We analyzed the electronic medical records of patients diagnosed
with AA who received care in the Department of Dermatology at the
Cleveland Clinic Foundation from 2005 to 2014. All AA diagnoses
were established by dermatologists. AA patients (n¼ 584) were
analyzed for (i) medical comorbidities and (ii) skin malignancies.
The prevalence of comorbidities and skin cancers was compared with
a control group, comprised of patients with diagnosis of seborrheic
dermatitis without any concomitant hair loss (n¼ 172).
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Table 2. Prevalence of skin cancers in patients with
alopecia areata
Characteristic
AA n=584
(%)
Control
n=172
(%) P-value OR (95% CI)
NMSC 13 (2.23) 8 (4.65) P=0.0889 0.467 (0.19–1.145)
BCC 9 (1.54) 6 (3.48) P=0.1074 0.433 (0.152–1.234)
SCC 3 (0.51) 1 (0.58) P=0.012 0.884 (0.092–8.44)
Melanoma 3 (0.51) 3 (1.74) P=0.1099 0.291 (0.058–1.454)
Abbreviations: AA, alopecia areata; BCC, basal-cell carcinoma; CI, con-
fidence interval; NMSC, non-melanoma skin cancers; OR, odds ratio; SCC,
squamous-cell carcinoma.
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